In myeloproliferative neoplasms (MPNs) and leukemia, sodium butyrate inhibits JAK2/STAT signaling through HDAC8-mediated upregulation of SOCS1 and SOCS3 (24). Here, SOCS3 is linked to myeloproliferative disorder.